2,3,7,8-tetrachlorodibenzo-p-dioxin induced Cell-Specific drug transporters with acquired cisplatin resistance in cisplatin sensitive cancer cells

Tuvshinjargal Gotovdorj, Eun Il Lee, Yongchul Lim, Eun Jeong Cha, Daeho Kwon, Eunyoung Hong, Yun Jeong Kim, Min Yeong Oh

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) can induce drug transporter genes such as the ATP-binding cassette G member 2 (ABCG2), which contributes to multidrug resistance. We investigated the effect of TCDD pretreatment on drug transporters induction from cancer cells of various origins. Cell viabilities after treatment of cisplatin were measured to evaluate acquiring cisplatin resistance by TCDD. Acquring cisplatin resistance was found only in cisplatin senstivie cancer cells including gastric SNU601, colon LS180, brain CRTMG and lymphoma Jurkat cells which showed a significant increase in cell viability after combined treatment with TCDD and cisplatin. High increase of ABCG2 gene expression was found in SNU601 and LS180 cells with a mild increase in the expression of the ABCC3, ABCC5,and SLC29A2 genes in SNU601 cells, and of major vault protein (MVP) in LS180 cells. The AhR inhibitor kaempferol suppressed the upregulation of ABCG2 expression and reversed the TCDD-induced increase in cell viability in LS180 cells. However, in CRT-MG cells, other transporter genes including ABCC1, ABCC5, ABCA3, ABCA2, ABCB4, ABCG1, and SLC29A1 were up-regulated. These findings suggested the acquiring cisplatin resistance by TCDD associated with cancer cell-type-specific induction of drug transporters.

Original languageEnglish
Pages (from-to)1188-1198
Number of pages11
JournalJournal of Korean Medical Science
Volume29
Issue number9
DOIs
Publication statusPublished - 2014

Fingerprint

Cisplatin
Pharmaceutical Preparations
Neoplasms
Cell Survival
Adenosine Triphosphate
Genes
Jurkat Cells
Polychlorinated Dibenzodioxins
Multiple Drug Resistance
Lymphoma
Stomach
Colon
Up-Regulation
Gene Expression
Brain

Keywords

  • ABCG2
  • Acquired cisplatin resistance
  • AhR
  • Drug transporters
  • TCDD

ASJC Scopus subject areas

  • Medicine(all)

Cite this

2,3,7,8-tetrachlorodibenzo-p-dioxin induced Cell-Specific drug transporters with acquired cisplatin resistance in cisplatin sensitive cancer cells. / Gotovdorj, Tuvshinjargal; Lee, Eun Il; Lim, Yongchul; Cha, Eun Jeong; Kwon, Daeho; Hong, Eunyoung; Kim, Yun Jeong; Oh, Min Yeong.

In: Journal of Korean Medical Science, Vol. 29, No. 9, 2014, p. 1188-1198.

Research output: Contribution to journalArticle

Gotovdorj, Tuvshinjargal ; Lee, Eun Il ; Lim, Yongchul ; Cha, Eun Jeong ; Kwon, Daeho ; Hong, Eunyoung ; Kim, Yun Jeong ; Oh, Min Yeong. / 2,3,7,8-tetrachlorodibenzo-p-dioxin induced Cell-Specific drug transporters with acquired cisplatin resistance in cisplatin sensitive cancer cells. In: Journal of Korean Medical Science. 2014 ; Vol. 29, No. 9. pp. 1188-1198.
@article{712780e6ba87433d8cc848b409fde432,
title = "2,3,7,8-tetrachlorodibenzo-p-dioxin induced Cell-Specific drug transporters with acquired cisplatin resistance in cisplatin sensitive cancer cells",
abstract = "2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) can induce drug transporter genes such as the ATP-binding cassette G member 2 (ABCG2), which contributes to multidrug resistance. We investigated the effect of TCDD pretreatment on drug transporters induction from cancer cells of various origins. Cell viabilities after treatment of cisplatin were measured to evaluate acquiring cisplatin resistance by TCDD. Acquring cisplatin resistance was found only in cisplatin senstivie cancer cells including gastric SNU601, colon LS180, brain CRTMG and lymphoma Jurkat cells which showed a significant increase in cell viability after combined treatment with TCDD and cisplatin. High increase of ABCG2 gene expression was found in SNU601 and LS180 cells with a mild increase in the expression of the ABCC3, ABCC5,and SLC29A2 genes in SNU601 cells, and of major vault protein (MVP) in LS180 cells. The AhR inhibitor kaempferol suppressed the upregulation of ABCG2 expression and reversed the TCDD-induced increase in cell viability in LS180 cells. However, in CRT-MG cells, other transporter genes including ABCC1, ABCC5, ABCA3, ABCA2, ABCB4, ABCG1, and SLC29A1 were up-regulated. These findings suggested the acquiring cisplatin resistance by TCDD associated with cancer cell-type-specific induction of drug transporters.",
keywords = "ABCG2, Acquired cisplatin resistance, AhR, Drug transporters, TCDD",
author = "Tuvshinjargal Gotovdorj and Lee, {Eun Il} and Yongchul Lim and Cha, {Eun Jeong} and Daeho Kwon and Eunyoung Hong and Kim, {Yun Jeong} and Oh, {Min Yeong}",
year = "2014",
doi = "10.3346/jkms.2014.29.9.1188",
language = "English",
volume = "29",
pages = "1188--1198",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "9",

}

TY - JOUR

T1 - 2,3,7,8-tetrachlorodibenzo-p-dioxin induced Cell-Specific drug transporters with acquired cisplatin resistance in cisplatin sensitive cancer cells

AU - Gotovdorj, Tuvshinjargal

AU - Lee, Eun Il

AU - Lim, Yongchul

AU - Cha, Eun Jeong

AU - Kwon, Daeho

AU - Hong, Eunyoung

AU - Kim, Yun Jeong

AU - Oh, Min Yeong

PY - 2014

Y1 - 2014

N2 - 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) can induce drug transporter genes such as the ATP-binding cassette G member 2 (ABCG2), which contributes to multidrug resistance. We investigated the effect of TCDD pretreatment on drug transporters induction from cancer cells of various origins. Cell viabilities after treatment of cisplatin were measured to evaluate acquiring cisplatin resistance by TCDD. Acquring cisplatin resistance was found only in cisplatin senstivie cancer cells including gastric SNU601, colon LS180, brain CRTMG and lymphoma Jurkat cells which showed a significant increase in cell viability after combined treatment with TCDD and cisplatin. High increase of ABCG2 gene expression was found in SNU601 and LS180 cells with a mild increase in the expression of the ABCC3, ABCC5,and SLC29A2 genes in SNU601 cells, and of major vault protein (MVP) in LS180 cells. The AhR inhibitor kaempferol suppressed the upregulation of ABCG2 expression and reversed the TCDD-induced increase in cell viability in LS180 cells. However, in CRT-MG cells, other transporter genes including ABCC1, ABCC5, ABCA3, ABCA2, ABCB4, ABCG1, and SLC29A1 were up-regulated. These findings suggested the acquiring cisplatin resistance by TCDD associated with cancer cell-type-specific induction of drug transporters.

AB - 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) can induce drug transporter genes such as the ATP-binding cassette G member 2 (ABCG2), which contributes to multidrug resistance. We investigated the effect of TCDD pretreatment on drug transporters induction from cancer cells of various origins. Cell viabilities after treatment of cisplatin were measured to evaluate acquiring cisplatin resistance by TCDD. Acquring cisplatin resistance was found only in cisplatin senstivie cancer cells including gastric SNU601, colon LS180, brain CRTMG and lymphoma Jurkat cells which showed a significant increase in cell viability after combined treatment with TCDD and cisplatin. High increase of ABCG2 gene expression was found in SNU601 and LS180 cells with a mild increase in the expression of the ABCC3, ABCC5,and SLC29A2 genes in SNU601 cells, and of major vault protein (MVP) in LS180 cells. The AhR inhibitor kaempferol suppressed the upregulation of ABCG2 expression and reversed the TCDD-induced increase in cell viability in LS180 cells. However, in CRT-MG cells, other transporter genes including ABCC1, ABCC5, ABCA3, ABCA2, ABCB4, ABCG1, and SLC29A1 were up-regulated. These findings suggested the acquiring cisplatin resistance by TCDD associated with cancer cell-type-specific induction of drug transporters.

KW - ABCG2

KW - Acquired cisplatin resistance

KW - AhR

KW - Drug transporters

KW - TCDD

UR - http://www.scopus.com/inward/record.url?scp=84929669274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929669274&partnerID=8YFLogxK

U2 - 10.3346/jkms.2014.29.9.1188

DO - 10.3346/jkms.2014.29.9.1188

M3 - Article

VL - 29

SP - 1188

EP - 1198

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 9

ER -